GSK3-IN-3 is a mitophagy inducer, inducing Parkin-dependent mitophagy . GSK3-IN-3 is also a GSK-3 inhibitor with an IC 50 value of 3.01 μM. GSK3-IN-3 is non-ATP nor substrate competitive and is neuroprotective against 6-OHDA In Vitro GSK3-IN-3 (VP07) (25 μM; 24 h) induces mitophagy in Parkin-expressing U2OS-iMLS cells with restricted potency. GSK3-IN-3 (1.56-25 μM; 24 h) results in mitochondria fission with mitochondrial morphology change in U2OS-iMLS-Parkin cells. GSK3-IN-3 (VP0.7) (5 μM, 10 μM; ) shows neuroprotection against 6-OHDA albeit in a Parkinson's disease in vitro cellular model in SH-SY5Y cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. ImmunofluorescenceCell Line: Parkin-expressing U2OS-iMLS cells Concentration: 1.56 μM, 3.12 μM, 6.25 μM, 12.5 μM, and 25 μM; Incubation Time: 24 hours Result: Induced a mitochondrial morphology change from a filament-shaped network to a more round-shaped network. Cell Viability AssayCell Line: SH-SY5Y cells Concentration: 0.5 μM, 1 μM, 3 μM, 5 μM, and 10 μM Incubation Time: 16 hours; with 35 μM 6-OHDA Result: Inhibited cell growth with an IC 50 value of 2.57 μM. Form:Solid IC50& Target:IC50: 3.01 μM (GSK-3)